HIV Integrase Inhibitors

Human Immunodeficiency Virus Integrase Strand Transfer Inhibitor

Organic Cation Transporter 2 Inhibitors

Multidrug and Toxin Extrusion Transporter 1 Inhibitors

Nucleoside Reverse Transcriptase Inhibitors

Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor

Acquired Immunodeficiency Syndrome

HIV Infections

<section class="Section" data-sectioncode="34089-3"><a name="ID_2511865c-6ab2-4e05-b973-5f5950062e35"></a><a name="section-10"></a><h1>11 DESCRIPTION</h1>DOVATO is a fixed-dose combination tablet containing dolutegravir (as dolutegravir sodium), an integrase strand transfer inhibitor (INSTI), and lamivudine (also known as 3TC), a nucleoside analogue reverse transcriptase inhibitor (NRTI).DOVATO tablets are for oral administration. Each film-coated tablet contains the active ingredients 50 mg of dolutegravir (equivalent to 52.6 mg dolutegravir sodium) and 300 mg of lamivudine and the inactive ingredients magnesium stearate, mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, sodium stearyl fumarate. The tablet film-coating contains the inactive ingredients hypromellose, polyethylene glycol, titanium dioxide.DolutegravirThe chemical name of dolutegravir sodium is sodium (4R,12aS)-9-{[(2,4-difluorophenyl)methyl]carbamoyl}-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazin-7-olate. The empirical formula is C20H18F2N3NaO5 and the molecular weight is 441.36 g/mol. It has the following structural formula:<div class="Figure"><a name="id1055358268"></a><img alt="Dolutegravir sodium chemical structure" src="dovato-spl-graphic-01.jpg"/></div>Dolutegravir sodium is a white to light yellow powder and is slightly soluble in water.LamivudineThe chemical name of lamivudine is (2R,cis)-4-amino-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one. Lamivudine is the (‑)enantiomer of a dideoxy analogue of cytidine. Lamivudine has also been referred to as (‑)2′,3′-dideoxy, 3′-thiacytidine. It has a molecular formula of C8H11N3O3S and a molecular weight of 229.3 g/mol. It has the following structural formula:<div class="Figure"><a name="id604849370"></a><img alt="Lamivudine chemical structure" src="dovato-spl-graphic-02.jpg"/></div>Lamivudine is a white to off‑white crystalline solid and is soluble in water.</section>

Dovato

dolutegravir

dolutegravir / lamivudine

dolutegravir 50 MG / lamivudine 300 MG Oral Tablet

dolutegravir 50 MG / lamivudine 300 MG Oral Tablet [Dovato]

lamivudine

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

ViiVConnect Enrollment Form 

ViiVConnect Online Portal - HCP Office 

Enroll in Patient Savings Program 

Viiv Healthcare Patient Assistance Program 

Common Patient Assistance Program Application (CPAPA)

Other HCP Resources 

About Dovato

Side Effects

Patient Stories 

Patient Resources

Doctor Discussion Guide 

Patient Brochure

Instructions For Use: HIV